Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide vs Metformin for CV Risk and Diabetes Remission
NCT06959784Phase 4Enrolling by invitation
- Sponsor
- China-Japan Friendship Hospital
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by China-Japan Friendship Hospital. Primary endpoints: Cardiovascular and cerebrovascular event risk score at 1 year, Major Adverse Cardiovascular Events at 96 weeks and 1 more. Started Jan 2024; status: enrolling by invitation.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06959784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06959784.